Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 May 1;80(3-4):338–343. doi: 10.1038/sj.bjc.6690360

Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents

G Colella 1, S Marchini 1, M D'Incalci 1, R Brown 2, M Broggini 1
PMCID: PMC2362350  PMID: 10408835

Abstract

Mismatch DNA repair deficiency is associated with resistance to certain major groove alkylating agents including methylating agents and cisplatin. We have now studied the relevance of mismatch repair alterations to the cytotoxicity induced by drugs which alkylate N3 adenines in the minor groove of DNA. We have used the mismatch repair defective human colocarcinoma cell line HCT-116 which has a mutation in the hMLH1 gene, and a subline where hMLH1 expression is restored by chromosome 3 transfer (HCT-116+ch3). We have tested three alkylating minor groove binders (tallimustine, carzelesin and CC1065) and one non-covalent minor groove binder (PNU 151807). The HCT-116+ch3 subline was more sensitive than the parental line to the treatment with the three alkylating minor groove binders, while the non-alkylating compound had a similar activity in both cell lines. Further support for mismatch repair being involved in sensitivity of the minor groove alkylators is that two cisplatin-resistant sublines of the human ovarian adenocarcinoma cell line A2780 (A2780/CP70 and A2780/MCP-1) are defective in hMLH1 expression and are more resistant to these agents than the parental mismatch repair proficient cells. Furthermore, the restoration of hMLH1 activity in the A2780/CP70 cell line, by introduction of chromosome 3, was associated with an increased sensitivity to the three alkylating minor groove binders. Again, the non-covalent minor groove binder was equally effective in mismatch repair deficient and proficient clones. The data indicate that mismatch repair deficiency mediated by loss of hMLH1 expression is associated not only with drug-resistance to major groove binders, but also to minor groove binders. However, loss of mismatch repair does not mediate resistance to the non-covalent minor groove binder PNU 151807. © 1999 Cancer Research Campaign

Keywords: minor groove binders, mismatch repair, alkylating agents

Full Text

The Full Text of this article is available as a PDF (116.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aebi S., Fink D., Gordon R., Kim H. K., Zheng H., Fink J. L., Howell S. B. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res. 1997 Oct;3(10):1763–1767. [PubMed] [Google Scholar]
  2. Aebi S., Kurdi-Haidar B., Gordon R., Cenni B., Zheng H., Fink D., Christen R. D., Boland C. R., Koi M., Fishel R. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 1996 Jul 1;56(13):3087–3090. [PubMed] [Google Scholar]
  3. Anthoney D. A., McIlwrath A. J., Gallagher W. M., Edlin A. R., Brown R. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res. 1996 Mar 15;56(6):1374–1381. [PubMed] [Google Scholar]
  4. Branch P., Aquilina G., Bignami M., Karran P. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature. 1993 Apr 15;362(6421):652–654. doi: 10.1038/362652a0. [DOI] [PubMed] [Google Scholar]
  5. Branch P., Hampson R., Karran P. DNA mismatch binding defects, DNA damage tolerance, and mutator phenotypes in human colorectal carcinoma cell lines. Cancer Res. 1995 Jun 1;55(11):2304–2309. [PubMed] [Google Scholar]
  6. Broggini M., Coley H. M., Mongelli N., Pesenti E., Wyatt M. D., Hartley J. A., D'Incalci M. DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin. Nucleic Acids Res. 1995 Jan 11;23(1):81–87. doi: 10.1093/nar/23.1.81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Broggini M., Erba E., Ponti M., Ballinari D., Geroni C., Spreafico F., D'Incalci M. Selective DNA interaction of the novel distamycin derivative FCE 24517. Cancer Res. 1991 Jan 1;51(1):199–204. [PubMed] [Google Scholar]
  8. Brown R., Hirst G. L., Gallagher W. M., McIlwrath A. J., Margison G. P., van der Zee A. G., Anthoney D. A. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene. 1997 Jul 3;15(1):45–52. doi: 10.1038/sj.onc.1201167. [DOI] [PubMed] [Google Scholar]
  9. D'Incalci M., Sessa C. DNA minor groove binding ligands: a new class of anticancer agents. Expert Opin Investig Drugs. 1997 Jul;6(7):875–884. doi: 10.1517/13543784.6.7.875. [DOI] [PubMed] [Google Scholar]
  10. Damia G., Imperatori L., Citti L., Mariani L., D'Incalci M. 3-methyladenine-DNA-glycosylase and O6-alkyl guanine-DNA-alkyltransferase activities and sensitivity to alkylating agents in human cancer cell lines. Br J Cancer. 1996 Apr;73(7):861–865. doi: 10.1038/bjc.1996.153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Damia G., Imperatori L., Stefanini M., D'Incalci M. Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents. Int J Cancer. 1996 Jun 11;66(6):779–783. doi: 10.1002/(SICI)1097-0215(19960611)66:6<779::AID-IJC12>3.0.CO;2-Z. [DOI] [PubMed] [Google Scholar]
  12. Drummond J. T., Anthoney A., Brown R., Modrich P. Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem. 1996 Aug 16;271(33):19645–19648. doi: 10.1074/jbc.271.33.19645. [DOI] [PubMed] [Google Scholar]
  13. Fink D., Nebel S., Aebi S., Zheng H., Cenni B., Nehmé A., Christen R. D., Howell S. B. The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 1996 Nov 1;56(21):4881–4886. [PubMed] [Google Scholar]
  14. Fink D., Zheng H., Nebel S., Norris P. S., Aebi S., Lin T. P., Nehmé A., Christen R. D., Haas M., MacLeod C. L. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res. 1997 May 15;57(10):1841–1845. [PubMed] [Google Scholar]
  15. Fishel R., Kolodner R. D. Identification of mismatch repair genes and their role in the development of cancer. Curr Opin Genet Dev. 1995 Jun;5(3):382–395. doi: 10.1016/0959-437x(95)80055-7. [DOI] [PubMed] [Google Scholar]
  16. Ghielmini M., Bosshard G., Capolongo L., Geroni M. C., Pesenti E., Torri V., D'Incalci M., Cavalli F., Sessa C. Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells. Br J Cancer. 1997;75(6):878–883. doi: 10.1038/bjc.1997.155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hurley L. H., Reynolds V. L., Swenson D. H., Petzold G. L., Scahill T. A. Reaction of the antitumor antibiotic CC-1065 with DNA: structure of a DNA adduct with DNA sequence specificity. Science. 1984 Nov 16;226(4676):843–844. doi: 10.1126/science.6494915. [DOI] [PubMed] [Google Scholar]
  18. Karran P., Bignami M. DNA damage tolerance, mismatch repair and genome instability. Bioessays. 1994 Nov;16(11):833–839. doi: 10.1002/bies.950161110. [DOI] [PubMed] [Google Scholar]
  19. Karran P., Hampson R. Genomic instability and tolerance to alkylating agents. Cancer Surv. 1996;28:69–85. [PubMed] [Google Scholar]
  20. Koi M., Umar A., Chauhan D. P., Cherian S. P., Carethers J. M., Kunkel T. A., Boland C. R. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res. 1994 Aug 15;54(16):4308–4312. [PubMed] [Google Scholar]
  21. Li L. H., DeKoning T. F., Kelly R. C., Krueger W. C., McGovren J. P., Padbury G. E., Petzold G. L., Wallace T. L., Ouding R. J., Prairie M. D. Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue. Cancer Res. 1992 Sep 15;52(18):4904–4913. [PubMed] [Google Scholar]
  22. Marchini S., Cozzi P., Beria I., Geroni C., Capolongo L., D'Incalci M., Broggini M. Sequence-specific DNA alkylation of novel tallimustine derivatives. Anticancer Drug Des. 1998 Apr;13(3):193–205. [PubMed] [Google Scholar]
  23. Martin D. G., Biles C., Gerpheide S. A., Hanka L. J., Krueger W. C., McGovren J. P., Mizsak S. A., Neil G. L., Stewart J. C., Visser J. CC-1065 (NSC 298223), a potent new antitumor agent improved production and isolation, characterization and antitumor activity. J Antibiot (Tokyo) 1981 Sep;34(9):1119–1125. doi: 10.7164/antibiotics.34.1119. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES